Why Is SUMMIT THERAPEUTICS (SMMT) Stock Down Today?
By the Top Tier Newswire AI Desk · November 17, 2026 at 10:08 AM ET · reviewed against 24 wire stories
SUMMIT THERAPEUTICS (SMMT) is down -6.13% in the latest session. Our newswire has captured 24 stories on SMMT across 13 sources in the last 36 hours, with AI sentiment reading bearish (avg 33/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Summit Therapeutics (SMMT) shares fell 6.13% to $11.10 as the FDA declined to approve its lung-cancer drug, ivonescimab. The regulator determined that the treatment needs to prove it can help patients live longer.
What Happened
The FDA issued a complete response letter for the biologics license application of ivonescimab. The agency cited a deficit in overall survival data, noting that while the drug showed a benefit in progression-free survival, it did not demonstrate a statistically significant improvement in how long patients lived. This decision blocked the approval of one of the biotech sector's most closely watched cancer drugs.
In the aftermath, several analysts adjusted their outlooks. Citigroup maintained a Buy rating but lowered its price target to $42.00. Barclays maintained an Equal Weight rating while cutting its price target to $18.00 from $20.00. The stock had already been under pressure, having dropped 16.7% over the previous eight trading sessions.
What The Data Shows
The stock opened at $11.95, a 1.1% gap up from the prior close of $11.82. It reached a session high of $12.08 at 8:20 AM ET before sliding to a low of $11.04 at 10:05 AM ET. Volume stood at 1.4 million shares, which is 0.3 times the three-month daily average. The company has a market capitalization of $11.3 billion and is currently unprofitable, with trailing twelve-month earnings per share of negative $1.07. Revenue for the same period declined 100.0%. The stock is trading near the bottom of its 52-week range, which spans from $11.53 to $29.23. On November 17, 2026, the stock printed nine fresh 52-week lows.
What To Watch
Coverage of the stock has been extensive, with 24 stories from 13 sources in the last 36 hours. Investors will monitor the company's next steps following the FDA's decision, as well as upcoming data for its other lung-cancer candidates.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
SMMT · Nov 17 session (5-min) · -9.90% vs prior close · updated 8:46 PM ETAI sentiment, last 36h · averaged over 24 stories · 33/100 bearish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
3d agoMorningstarBEARISH 22General
The FDA declined to approve one of biotech's most closely watched cancer drugs. The company's stock tumbled.
The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.
3d agoStockTitanNEUTRAL 48General
San Mateo Midstream Prices Upsized Offering of $850 Million of Senior Notes Due 2031
3d agoBarron'sBEARISH 38General
U.S. Indexes Dropped Monday; Summit Therapeutics Fell Furthest
3d agoSeeking AlphaBEARISH 42Analyst
Summit Therapeutics: Still A Hold As The 2L Gamble Fails And 1L Data Looms
Summit Therapeutics remains a
3d agoGuruFocusBEARISH 42Analyst
SMMT Maintained by Citigroup -- Price Target Lowered to $42.00
4d agoThe FlyBEARISH 34General
Summit Therapeutics Falls 14 4
4d agoGuruFocusBEARISH 42Analyst
SMMT Maintained by Barclays -- Price Target Lowered to $18.00
4d agoStocktwits NewsBEARISH 34Analyst
SMMT Stock Sees Price Target Reductions – A Look At What Analysts Said About FDA’s Complete Response Letter
Barclays lowered its price target on Summit Therapeutics to $18 from $20 while maintaining an 'Equal Weight' rating, according to The Fly.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →